<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D878FB57-FB53-44E3-A356-AE364FC540EE"><gtr:id>D878FB57-FB53-44E3-A356-AE364FC540EE</gtr:id><gtr:name>University Hospital of North Staffordshire NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7008F77D-D7F3-4558-AEE7-9195B7890A2D"><gtr:id>7008F77D-D7F3-4558-AEE7-9195B7890A2D</gtr:id><gtr:name>Moorfields Eye Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/55B08AB5-DB58-4FCE-9037-1D4179E0F4E3"><gtr:id>55B08AB5-DB58-4FCE-9037-1D4179E0F4E3</gtr:id><gtr:name>The Walton Centre NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Lower Lane</gtr:line1><gtr:city>Fazakerley</gtr:city><gtr:postCode>L9 7LJ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CE57A442-8B1B-474B-97CF-118DD4823590"><gtr:id>CE57A442-8B1B-474B-97CF-118DD4823590</gtr:id><gtr:name>Gloucestershire Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D878FB57-FB53-44E3-A356-AE364FC540EE"><gtr:id>D878FB57-FB53-44E3-A356-AE364FC540EE</gtr:id><gtr:name>University Hospital of North Staffordshire NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7008F77D-D7F3-4558-AEE7-9195B7890A2D"><gtr:id>7008F77D-D7F3-4558-AEE7-9195B7890A2D</gtr:id><gtr:name>Moorfields Eye Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/55B08AB5-DB58-4FCE-9037-1D4179E0F4E3"><gtr:id>55B08AB5-DB58-4FCE-9037-1D4179E0F4E3</gtr:id><gtr:name>The Walton Centre NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Lower Lane</gtr:line1><gtr:city>Fazakerley</gtr:city><gtr:postCode>L9 7LJ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CE57A442-8B1B-474B-97CF-118DD4823590"><gtr:id>CE57A442-8B1B-474B-97CF-118DD4823590</gtr:id><gtr:name>Gloucestershire Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D7920E60-F413-49B0-AEB7-03A29C3072D7"><gtr:id>D7920E60-F413-49B0-AEB7-03A29C3072D7</gtr:id><gtr:firstName>Alexandra</gtr:firstName><gtr:surname>Sinclair</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F00B2D5C-D593-448D-81CF-25F4A56DC57D"><gtr:id>F00B2D5C-D593-448D-81CF-25F4A56DC57D</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Tomlinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/471E482C-C060-4EF1-BE25-288F2B4C9681"><gtr:id>471E482C-C060-4EF1-BE25-288F2B4C9681</gtr:id><gtr:firstName>Hitesh</gtr:firstName><gtr:surname>Sanganee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/90300D17-7BE0-4E54-B57F-4F4569547B87"><gtr:id>90300D17-7BE0-4E54-B57F-4F4569547B87</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Stewart</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FK015184%2F1"><gtr:id>F0FD45C6-0014-4EFD-9DEA-880A428E988D</gtr:id><gtr:title>MICA: Assessing the therapeutic efficacy of 11beta-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K015184/1</gtr:grantReference><gtr:abstractText>Idiopathic intracranial hypertension (IIH), a condition of raised brain pressure, is a common cause of blindness in young overweight women. The underlying cause of the condition has not been fully established and the best way to treat IIH is not known. Drugs such as acetazolamide, have not been shown to be effective and additionally have intolerable side effects. Brain fluid shunting surgery can be used to save vision, but shunts block in over half of patients and therefore need replacing, often multiple times. Treatments such as weight loss are notoriously difficult. Our recent research has highlighted the potential role of an enzyme that generates steroid locally in brain tissues. 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) generates active steroid within the parts of the brain that produce cerebrospinal fluid (CSF) - the fluid that bathes the brain. Production of too much CSF can lead to increased brain pressure in IIH and we believe that 11beta-HSD1 drives this process in IIH. Additionally, we have demonstrated that weight loss and brain pressure reduction which significantly improve IIH also reduced 11beta-HSD1 activity. We therefore suggest that reducing 11beta-HSD1, with an oral tablet of AZD4017 (an inhibitor of 11beta-HSD1 developed by AstraZeneca) may represent a landmark treatment for IIH.
Through a partnership between AstraZeneca and University of Birmingham we will conduct a randomised, blinded, clinical study (24 patients) to look at the effectiveness, safety and side effects of AZD4017 in the treatment of IIH. Patients will undergo a series of investigations to assess brain pressure (through a lumbar puncture), vision and headaches at the start and end of the 3 month study. We will also be conducting regular monitoring of urine and blood alongside detailed patient assessments to evaluate drug safety and side effects.
This will be the first study to investigate the role of 11beta-HSD1 inhibitors in IIH and has the potential to offer a novel treatment in this condition which can cause blindness. Additionally, if effective, AZD4017 may have uses in other neurological conditions where the morbidity is related to elevated brain pressure.</gtr:abstractText><gtr:technicalSummary>Idiopathic intracranial hypertension (IIH), is a common condition of unknown aetiology affecting the young obese female population (20 per 100,000). Faced with the global obesity epidemic, its incidence is expected to rise further. IIH is characterised by elevated intracranial pressure (ICP) which manifests as disabling headaches and severe visual loss in up to 25% of patients. An evidence base for treatment has not been established and there are currently no effective and tolerable pharamcotherapeutic options. Based upon our in-vitro observations, we have hypothesised that increased local glucocorticoid generation through the activity of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) within the choroid plexus that generates cerebrospinal fluid (excess production leading to raised ICP) is crucial to the pathogenesis of IIH. This mechanism is analogous to that occurring in the ocular ciliary body which produces aqueous humor where 11beta-HSD1 inhibitors have been shown to lower intraocular pressure. We have recently published a seminal study in patients with IIH and demonstrated that weight loss significantly reduced 11beta-HSD1 activity, ICP and dramatically improved patient symptoms; the observed reduction in ICP correlated directly with the reduction in ICP. 

In collaboration with our industrial partner, AstraZeneca (AZ), we will conduct a double blind, placebo controlled randomised phase II study to assess the tolerability, safety and efficacy of the selective 11beta-HSD1 inhibitor, AZD4017, in the treatment of IIH. The study will be conducted at University Hospitals Birmingham NHS Foundation Trust, the Midlands Eye Centre and the Wellcome Trust Clinical Research Facility. In total, 24 patients with active chronic IIH (raised ICP and papilloedema) will be randomised to AZD4017 or placebo tablets (1:1).The primary outcome measure, intracranial pressure, will be evaluated by lumbar puncture at 12 weeks compared to baseline.</gtr:technicalSummary><gtr:potentialImpactText>Over the last 2 decades, the investigators on this proposal have established glucocorticoid regeneration through the activity of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) as a therapeutic target in many conditions including idiopathic intracranial hypertension (IIH). They have published many of the seminal studies in the highest impact journals (Lancet, JCI, BMJ, Nature Genetics). Reflecting the impact of their work, in 2011, 11beta-HSD1 ranked as the 2nd most popular pharmaceutical drug target in terms of number of patents filed (&amp;gt;40 US patents, &amp;gt;90 EU patents). They have now established a unique academic-industrial collaboration between University of Birmingham and AstraZeneca (AZ) to trial the selective 11beta-HSD1 inhibitor, AZD4017 in a defined population of patients with IIH. Within this collaboration, AZ have provided the active compound and placebo as well as all relevant preclinical and phase I clinical data to facilitate study design based upon the academic hypothesis. Complementing this, UoB have brought clinical trial expertise and state-of-the-art methodologies combining neurology, ophthalmology and endocrinology. The close working relationship between University Hospital Birmingham NHS trust and the Birmingham and Midlands Eye Centre which together provide one of the largest IIH services in the country will ensure that sufficient patients are recruited through the dedicated neuro-ophthalmology clinics.
On a global level, the impact of this successful collaboration between UoB and AZ will serve as a model for other academic institutions and pharmaceutical company interactions and it is hoped that this will be adopted nationally and internationally. There are clear additional benefits of these collaborations for patients and non-academics. Patients will have the potential access to new and emerging treatments sooner than would otherwise have been possible. Furthermore, it provides the opportunity to consider indications for drug therapy that may not have been considered by the pharmaceutical company.
The specific academic impact is clear and this proposal will add significantly to the field representing the first clinical trial of this class of drug in patients with IIH. Positive results from this study targeting glucocorticoid metabolism will undoubtedly pave the way for future drug development. The impact upon patient care has the potential to be equally impressive offering a new treatment in a condition where currently proven efficacious pharmacotherapies are lacking.
In conclusion, this proposal is one of the crucial chapters in the '11beta-HSD1 story' that has developed from target identification and validation through to drug development and now to trials in disease populations. It is this final component that adds the greatest impact both academically, but perhaps more importantly to patients with the aim of improving health care.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-08-11</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-12</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>408146</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK IIH Research Network</gtr:description><gtr:id>0F7EF238-CCE0-4EEA-A4EF-987AD38AD6BF</gtr:id><gtr:impact>Multi-discplinary - neurology and ophthalmology</gtr:impact><gtr:partnerContribution>They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.</gtr:partnerContribution><gtr:piContribution>The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials.

This has involved:
o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist)
o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist)
o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist)
o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist)
Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of North Staffordshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University Hospital of North Staffordshire</gtr:department><gtr:description>UK IIH Research Network</gtr:description><gtr:id>CCEEB594-C943-48A2-8795-B649E4062269</gtr:id><gtr:impact>Multi-discplinary - neurology and ophthalmology</gtr:impact><gtr:partnerContribution>They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.</gtr:partnerContribution><gtr:piContribution>The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials.

This has involved:
o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist)
o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist)
o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist)
o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist)
Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moorfields Eye Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>OCT interpretation</gtr:description><gtr:id>27E899E2-F567-4BFF-8451-0D3239D4BC51</gtr:id><gtr:impact>Multi-disciplinary - ophthalmology / neurology</gtr:impact><gtr:partnerContribution>Dr Pearse Keane has aided in assessing the quality of and giving advice on the interpretation of optical coherence tomography, which has improved assessments used in both IIH:WT and IIH:DT trials.</gtr:partnerContribution><gtr:piContribution>None so far</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>King's College Hospital</gtr:department><gtr:description>UK IIH Research Network</gtr:description><gtr:id>83A9670B-EFC3-456E-8FAF-EEDD7E29575C</gtr:id><gtr:impact>Multi-discplinary - neurology and ophthalmology</gtr:impact><gtr:partnerContribution>They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.</gtr:partnerContribution><gtr:piContribution>The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials.

This has involved:
o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist)
o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist)
o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist)
o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist)
Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gloucestershire Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Gloucestershire Royal Hospital</gtr:department><gtr:description>UK IIH Research Network</gtr:description><gtr:id>CA37D4CC-9A59-4F6B-89FE-F4F32660130C</gtr:id><gtr:impact>Multi-discplinary - neurology and ophthalmology</gtr:impact><gtr:partnerContribution>They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.</gtr:partnerContribution><gtr:piContribution>The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials.

This has involved:
o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist)
o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist)
o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist)
o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist)
Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Leicester NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Leicester General Hospital</gtr:department><gtr:description>UK IIH Research Network</gtr:description><gtr:id>952E5E6F-8830-48A4-9C73-8F14278D6602</gtr:id><gtr:impact>Multi-discplinary - neurology and ophthalmology</gtr:impact><gtr:partnerContribution>They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.</gtr:partnerContribution><gtr:piContribution>The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials.

This has involved:
o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist)
o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist)
o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist)
o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist)
Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walton Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Walton Centre</gtr:department><gtr:description>UK IIH Research Network</gtr:description><gtr:id>CD90EEEE-C17A-44B1-9FBC-282EF39B1DE2</gtr:id><gtr:impact>Multi-discplinary - neurology and ophthalmology</gtr:impact><gtr:partnerContribution>They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.</gtr:partnerContribution><gtr:piContribution>The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials.

This has involved:
o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist)
o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist)
o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist)
o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist)
Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Hallamshire Hospital</gtr:department><gtr:description>UK IIH Research Network</gtr:description><gtr:id>937DA5DF-02F5-44FA-B61B-2D34ECE1A197</gtr:id><gtr:impact>Multi-discplinary - neurology and ophthalmology</gtr:impact><gtr:partnerContribution>They have become sites or identification sites for the IIH:DT and IIH:WT trials. Future contributions will be recruiting participants to trials.</gtr:partnerContribution><gtr:piContribution>The partnership has been to establish the foundations of a UK-wide research network in IIH. Our contributions have been to set up the trials, approach and involve collaborators, and set them up as research sites in the IIH:DT and IIH:WT trials.

This has involved:
o King's College London, Professor Peter Goadsby (Honorary Consultant Neurologist) and Mr Eoin O'Sullivan (Consultant Ophthalmologist)
o The Walton Centre, Liverpool, Dr Nick Silver, Dr Anita Krishnan (Consultant Neurologists) and Mrs Carmel Noonan (Consultant Ophthalmologist)
o Royal Hallamshire Hospital Sheffield, Dr Simon Hickman (Consultant Neurologist)
o Southern General Hospital Glasgow, Dr Alok Tyagi (Consultant Neurologist)
Dr Ben Wakerley (Gloucester / Oxford), Dr Simon Hickman (Royal Hallamshire), Dr Mark Lawden (Leicester General) and Dr Brendan Davies (Staffordshire).</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>IIH UK national patient conference June 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>981E6411-36EF-4A84-967B-58547D0C56BA</gtr:id><gtr:impact>Informing, generated discussion and questions from patients:
? Invited speaker at the IIH UK national patient conference June 2015, Birmingham, UK.

generated interest and enquiries to participate in our clinical trial portfolio</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>?	Chair and Invited Speaker at the European Neuro-Ophthalmology Society Conference, Oxford, UK. 11/04/13</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EC853F2A-DE49-4C55-BA80-0005931A1731</gtr:id><gtr:impact>Invited to Chaired a morning session and organised the speaker list. Then invited to present my research on Idiopathic Intracranial Hypertension

Oxford, UK. 11/04/13
title: Obesity and the Female Brain: a High Pressure situation!

Multiple offers of collaboarion internationally</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patron of IIH UK patient charity</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>138B0FA2-F84B-456D-BE16-AC5F19DB46FD</gtr:id><gtr:impact>Being patron of the main IIH patient charity in the UK has led to closer collaboration with the charity. This has led to their involvement in Patient and Public Involvement aspects of my trials, and to their help with publicising the trials.

I have been able to work with the charity trustees to suggest direction for research, and have received their help in patient surveys to preview/inform research questions, for example.

We have had patients contact the trials team to then take part in the trials that we would not have otherwise reached. The trials website receive more traffic when the charity's promotion of them/the trials is more active.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.iih.org.uk</gtr:url><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Head of the Cerebrospinal Fluid Disorders Research Group, University of Birmingham</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>971A34DB-6BD7-4632-88BA-D21C33EE71BC</gtr:id><gtr:impact>Regular working group (quarterly) and dicussions to enhance collaborations (local and international)

organising visiting professors from USA to teach skills and write collaborative grants</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IIH:DT presentation at West Midlands CSF Dysorders Symposium 2014</gtr:description><gtr:id>F6E19F41-91F7-4DFD-A595-B05A6A3C431F</gtr:id><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>?	Invited Speaker at UK Neuro-Ophthalmology Special Interest Group Conference,  Glasgow. 13/03/13</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D330E1A0-D734-4B23-AF40-1347926FF50A</gtr:id><gtr:impact>Conference - UK Neuro-Ophthalmology 
Title: Idiopathic Intracranial Hypertension: What do we need to know......?
Glasgow. 13/03/13

Collaborations and dissemination of research findings</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow Southern General Hospital Oct 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7FC92600-E8AE-4084-92D0-3AF654788702</gtr:id><gtr:impact>Informing, generated discussion and question

Increased interest in clinical trial portfolio</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IIH UK Patient charity talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3D2FD7E7-3893-4BA8-81F2-03672C1D4387</gtr:id><gtr:impact>The presentation resulted in a substantial question and answer session with discussion from the audience. Afterwards, the trials team were approached for information on the trials, including information on how to participate, with some patients giving details to be contacted by the team to take part.

After this patient conference the trials team received an increased number of requests for information about or participation in their trials. The trials websites received increased traffic after the conference (doubled in June 2015).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.iih.org.uk/index.php?option=com_content&amp;view=article&amp;id=91</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>? Midland Neuroscience Teaching &amp;amp; Research Fund</gtr:description><gtr:fundingOrg>Midland Neuroscience Teaching and Research Fund</gtr:fundingOrg><gtr:id>680E8271-CA65-4737-BDAE-DE1A28777A50</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Impacted on how IIH is treated internationally (following IIH weight trial) - data presented in presenttions and numerous review papers</gtr:description><gtr:id>E9A8FE30-3C84-4E69-9EDF-CBC8C7598B63</gtr:id></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:id>033D823A-F081-46BB-AA10-33215DCACEF4</gtr:id><gtr:title>IIH:DT RCT (?	Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the therapeutic efficacy and safety of an 11?-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017))</gtr:title></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:id>AB82966A-1AEB-44D5-9E90-F11A8F465158</gtr:id><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IIH:Life</gtr:title></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/340E661D-E448-483D-AB33-C91FCFEAE43E"><gtr:id>340E661D-E448-483D-AB33-C91FCFEAE43E</gtr:id><gtr:title>A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d54e7f2e129804e49adb169604bf9392"><gtr:id>d54e7f2e129804e49adb169604bf9392</gtr:id><gtr:otherNames>Mollan SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2D1BF283-D3A8-45B1-B433-6CE7A03BBA72"><gtr:id>2D1BF283-D3A8-45B1-B433-6CE7A03BBA72</gtr:id><gtr:title>Headache management: pharmacological approaches.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7220211dc580d13dbccb0f238a27462d"><gtr:id>7220211dc580d13dbccb0f238a27462d</gtr:id><gtr:otherNames>Sinclair AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6318EE7F-FC34-4E41-ACFE-B739D92F0B94"><gtr:id>6318EE7F-FC34-4E41-ACFE-B739D92F0B94</gtr:id><gtr:title>Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions</gtr:title><gtr:parentPublicationTitle>The Lancet Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/62f42bfdc74751dbe4503d80269109d5"><gtr:id>62f42bfdc74751dbe4503d80269109d5</gtr:id><gtr:otherNames>Markey K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9A301A5-CB25-4650-8D54-E22DB8736584"><gtr:id>C9A301A5-CB25-4650-8D54-E22DB8736584</gtr:id><gtr:title>Idiopathic intracranial hypertension, hormones, and 11?-hydroxysteroid dehydrogenases.</gtr:title><gtr:parentPublicationTitle>Journal of pain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52719f16dc1b722347444e01e4481083"><gtr:id>52719f16dc1b722347444e01e4481083</gtr:id><gtr:otherNames>Markey KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1178-7090</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9E2D083-436F-490F-B4D5-AAA996A13F67"><gtr:id>E9E2D083-436F-490F-B4D5-AAA996A13F67</gtr:id><gtr:title>Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3371bf5bd214349b10832ad888e2b5a7"><gtr:id>3371bf5bd214349b10832ad888e2b5a7</gtr:id><gtr:otherNames>Clayton RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC067D29-1E03-4490-8CBB-708E2D78B586"><gtr:id>FC067D29-1E03-4490-8CBB-708E2D78B586</gtr:id><gtr:title>11?-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.</gtr:title><gtr:parentPublicationTitle>Endocrine reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7416d802fac8c54a0a20f10e58737ab1"><gtr:id>7416d802fac8c54a0a20f10e58737ab1</gtr:id><gtr:otherNames>Gathercole LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0163-769X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF1D514A-3164-432E-B80D-96346689E0F4"><gtr:id>CF1D514A-3164-432E-B80D-96346689E0F4</gtr:id><gtr:title>Idiopathic intracranial hypertension; research progress and emerging themes.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d42a938f55aeb5889222f86e63e45f9"><gtr:id>8d42a938f55aeb5889222f86e63e45f9</gtr:id><gtr:otherNames>Batra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CD7E4D4E-F118-4453-B15A-A8CF285CD4EA"><gtr:id>CD7E4D4E-F118-4453-B15A-A8CF285CD4EA</gtr:id><gtr:title>Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b5d8ef8943d35a20e95fca492fd3713e"><gtr:id>b5d8ef8943d35a20e95fca492fd3713e</gtr:id><gtr:otherNames>Stewart PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E77E83E8-D414-48B2-9648-C737C4459577"><gtr:id>E77E83E8-D414-48B2-9648-C737C4459577</gtr:id><gtr:title>Male 11?-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/74757ba33a4f5d12d4ab5eea50de0695"><gtr:id>74757ba33a4f5d12d4ab5eea50de0695</gtr:id><gtr:otherNames>Larner DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6210FBF-5704-4C3E-9E46-17F3A9C579D3"><gtr:id>C6210FBF-5704-4C3E-9E46-17F3A9C579D3</gtr:id><gtr:title>Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d54e7f2e129804e49adb169604bf9392"><gtr:id>d54e7f2e129804e49adb169604bf9392</gtr:id><gtr:otherNames>Mollan SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/266F0E3E-770E-4EB8-9628-ADABA577E9F4"><gtr:id>266F0E3E-770E-4EB8-9628-ADABA577E9F4</gtr:id><gtr:title>Migraine, cerebrovascular disease and the metabolic syndrome.</gtr:title><gtr:parentPublicationTitle>Annals of Indian Academy of Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7220211dc580d13dbccb0f238a27462d"><gtr:id>7220211dc580d13dbccb0f238a27462d</gtr:id><gtr:otherNames>Sinclair AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0972-2327</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6ED81826-F889-44BF-A5BF-40B8ADDBE3A3"><gtr:id>6ED81826-F889-44BF-A5BF-40B8ADDBE3A3</gtr:id><gtr:title>Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d54e7f2e129804e49adb169604bf9392"><gtr:id>d54e7f2e129804e49adb169604bf9392</gtr:id><gtr:otherNames>Mollan SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B2DA5E17-2731-4C64-9234-5BC101E1C7F9"><gtr:id>B2DA5E17-2731-4C64-9234-5BC101E1C7F9</gtr:id><gtr:title>Glucocorticoids and 11?-HSD1 are major regulators of intramyocellular protein metabolism.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50266dbb5bd134a51e37cc9434e56cf3"><gtr:id>50266dbb5bd134a51e37cc9434e56cf3</gtr:id><gtr:otherNames>Morgan SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8CDB38B3-2B7B-4408-9262-2AE9A88082E2"><gtr:id>8CDB38B3-2B7B-4408-9262-2AE9A88082E2</gtr:id><gtr:title>Should we educate about the risks of medication overuse headache?</gtr:title><gtr:parentPublicationTitle>The journal of headache and pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7eccb83f6e362a15de43c5618b7170f8"><gtr:id>7eccb83f6e362a15de43c5618b7170f8</gtr:id><gtr:otherNames>Lai JT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1129-2369</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E76EAE91-500C-4465-B03A-FCAEC50C522A"><gtr:id>E76EAE91-500C-4465-B03A-FCAEC50C522A</gtr:id><gtr:title>High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/179964427664d560060191a8a6c31cf4"><gtr:id>179964427664d560060191a8a6c31cf4</gtr:id><gtr:otherNames>Jenkinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9865DCBF-9393-43DD-970B-0846B61F8552"><gtr:id>9865DCBF-9393-43DD-970B-0846B61F8552</gtr:id><gtr:title>Diffusion tensor imaging with direct cytopathological validation: characterisation of decorin treatment in experimental juvenile communicating hydrocephalus.</gtr:title><gtr:parentPublicationTitle>Fluids and barriers of the CNS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/484ee18cb24199ea52e1d818d9cfeadb"><gtr:id>484ee18cb24199ea52e1d818d9cfeadb</gtr:id><gtr:otherNames>Aojula A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-8118</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17AC028C-C40B-4516-8682-11BE88783E18"><gtr:id>17AC028C-C40B-4516-8682-11BE88783E18</gtr:id><gtr:title>Comment on the Idiopathic Intracranial Hypertension Treatment Trial. JAMA Letter to the Editor</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9dadbd3b1f61f929eda1cb526242b06f"><gtr:id>9dadbd3b1f61f929eda1cb526242b06f</gtr:id><gtr:otherNames>Mollan S</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E12614CF-3D5D-4851-BCC2-F376AC73D6CE"><gtr:id>E12614CF-3D5D-4851-BCC2-F376AC73D6CE</gtr:id><gtr:title>SFRP2 Is Associated with Increased Adiposity and VEGF Expression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6faad224b0d9f2591b7db726f3b40c7a"><gtr:id>6faad224b0d9f2591b7db726f3b40c7a</gtr:id><gtr:otherNames>Crowley RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9448A129-DC36-4FB8-BB89-A98198146F29"><gtr:id>9448A129-DC36-4FB8-BB89-A98198146F29</gtr:id><gtr:title>Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/015b14afa6b5b3668d14f53b709742c8"><gtr:id>015b14afa6b5b3668d14f53b709742c8</gtr:id><gtr:otherNames>Weigel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8506AFA-D5E9-4A16-94F8-2DE832ECDF66"><gtr:id>D8506AFA-D5E9-4A16-94F8-2DE832ECDF66</gtr:id><gtr:title>Acromegaly.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/01dc0ed26132145d0eddfb05f09f7965"><gtr:id>01dc0ed26132145d0eddfb05f09f7965</gtr:id><gtr:otherNames>Dineen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7080CA59-FE0F-4857-B653-3582350CE120"><gtr:id>7080CA59-FE0F-4857-B653-3582350CE120</gtr:id><gtr:title>11?-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88d98bf3954a69fc156c27af9fb0725e"><gtr:id>88d98bf3954a69fc156c27af9fb0725e</gtr:id><gtr:otherNames>Hardy RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K015184/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>